ArticleCommunications medicine2025
Exploring predictors of post-COVID-19 condition among 810 851 individuals in Sweden.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Booster dose of COVID-19 vaccine and its effectiveness against post COVID-19 condition in individuals with pre-existing immunity: a sequential propensity score-matched cohort study.EClinicalMedicine · 2026Article
- SARS-CoV-2 infection and COVID-19 vaccination and the risk for new-onset type 1 diabetes: a register-based population study in Sweden.Diabetologia · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundLong-term effects of COVID-19 can place burden on individuals, healthcare, and society. We aimed to evaluate the importance of a wide range of potential risk factors for being diagnosed with post-COVID-19 condition (PCC).
methodsWe used data from national and regional registers and databases for all adult residents in the two largest regions in Sweden. Individuals with a first COVID-19 between 1 August 2020 and 9 February 2022 were included and followed until PCC diagnosis, censoring (death or migration), or 30 November 2023. Using Cox proportional hazards models and backwards stepwise selection, we evaluated a large set of risk factors including sociodemographic data, comorbidities, healthcare contact behaviors, COVID-19-related factors, as well as PCC in family and cohabitants (as proxies for genetics and shared environment).
resultsWe include 810,851 individuals (age range 18-106 years and 53.3% women), of whom 1.4% are diagnosed with PCC during follow-up. Female sex, older age, being born outside Sweden, higher educational attainment, essential workers, having comorbidities such as thromboembolic disease, asthma, fibromyalgia, depression/anxiety, and stress-related disorders, being infected earlier in the study period, experiencing severe acute COVID-19, not being vaccinated before COVID-19, and having a relative or a cohabitant with PCC are associated with an increased risk of being diagnosed with PCC.
conclusionsIn this large population-based cohort study, our exploratory analysis reveals several risk factors for being diagnosed with PCC. Our findings can serve as a basis for future targeting of preventive measures against PCC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.